Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Clozel

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Cell and Tissue Research|February 27, 1999
The endothelin system in human and monkey ovaries: in situ gene expression of the different componentsH Karam, O Valdenaire, M F Belair, et al.
Journal of Cardiovascular Pharmacology|January 1, 1996
Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteriesP H Dagassan, V Breu, M Clozel, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral useM Clozel, H Ramuz, J P Clozel, et al.
European Journal of Biochemistry|July 1, 1995
Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptorsV Breu, K Hashido, C Broger, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1994
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonistM Clozel, V Breu, G A Gray, et al.
Circulation|November 24, 1998
Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery diseaseR R Wenzel, M Fleisch, S Shaw, et al.
Nature|October 21, 1993
Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonistM Clozel, V Breu, K Burri, et al.
The Journal of Biological Chemistry|November 21, 1998
A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis-induced renal failureK P Moore, S G Holt, R P Patel, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Cell and Tissue Research|February 27, 1999
The endothelin system in human and monkey ovaries: in situ gene expression of the different componentsH Karam, O Valdenaire, M F Belair, et al.
Journal of Cardiovascular Pharmacology|January 1, 1996
Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteriesP H Dagassan, V Breu, M Clozel, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral useM Clozel, H Ramuz, J P Clozel, et al.
European Journal of Biochemistry|July 1, 1995
Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptorsV Breu, K Hashido, C Broger, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1994
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonistM Clozel, V Breu, G A Gray, et al.
Circulation|November 24, 1998
Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery diseaseR R Wenzel, M Fleisch, S Shaw, et al.
Nature|October 21, 1993
Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonistM Clozel, V Breu, K Burri, et al.
The Journal of Biological Chemistry|November 21, 1998
A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis-induced renal failureK P Moore, S G Holt, R P Patel, et al.
Pageof 9